Lung cancer

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study. The discovery was made by researchers at Washington University School of Medicine in St Louis, Grenoble Alpes University in Grenoble in France, and The University of Texas MD Anderson Cancer […]

Scientists have discovered a new combination of drugs that could act as a promising treatment for people with certain types of lung cancer.  Lung cancer is one of the most common cancers in the world. Every year, it’s thought that around 2.21 million people die due to lung cancer, according to the World Health Organisation […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Takeda’s EXKIVITY (mobocertinib) for patients in Great Britain with a rare and aggressive form of non-small cell lung cancer (NSCLC).   The authorisation means that EXKIVITY (mobocertinib) will be made available as a treatment for adult patients with epidermal growth factor […]

Arctoris and Evariste Technologies have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients with Non-Small Cell Lung Cancer (NSCLC).   Current treatment options  Current treatment options for NSCLC are limited, especially in advanced stages. It has been shown that the proto-oncogene cMet is mutated or upregulated in approximately 5% […]

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1  Context  Lung cancer accounts for a quarter of all cancer deaths in Scotland, […]

AstraZeneca’s Tagrisso (osimertinib) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC) for the treatment of early-stage lung cancer.   Osimertinib will be used as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor (EGFR) exon 19 deletions or […]